SAN DIEGO, October 30, 2025 — Leads & Copy — Resmed Inc. (NYSE: RMD, ASX: RMD) reported its quarter ended September 30, 2025, with revenue up 9% to $1.3 billion and non-GAAP diluted earnings per share of $2.55.
Resmed’s Chairman and CEO, Mick Farrell, noted the strong start to fiscal year 2026, citing a 9% revenue increase and a 280 basis point expansion in non-GAAP gross margin. He added that the results reinforced the company’s strategy to transform healthcare in the home with hardware, software, and solutions that people love. The company remains committed to ongoing operational excellence and strategic investment in innovation.
Other highlights include a study in The Lancet Respiratory Medicine projecting 77 million U.S. adults with OSA by 2050 and dual Red Dot Product Design 2025 awards for the AirTouch N30i. Additionally, the company launched the Sleep Institute and announced the election of Nicole Mowad-Nassar to its board.
The board declared a quarterly cash dividend of $0.60 per share, payable on December 18, 2025, to holders of record as of November 13, 2025.
For investors: +1 858-221-3304, investorrelations@resmed.com; For media: +1 619-510-1281, news@resmed.com
Source: Resmed
